Analyst Viewpoint
Increase in incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving the global market. Proteins play a crucial role in various biological processes, and leveraging their therapeutic potential has paved the way for innovative treatments for a wide range of diseases. Advancements in biotechnology and genetic engineering enabling large-scale production of therapeutic proteins and addressing the challenges associated with sourcing proteins from natural origins is another factor propelling market expansion. Furthermore, growth of the biosimilars market is likely to fuel the global protein therapeutics market size during the forecast period.
Advancements in protein engineering and formulation techniques offer lucrative opportunities to protein therapeutics market players. Companies are focusing on developing personalized medicine, with emphasis on targeted therapies tailored to individual patients based on their genetic makeup and disease characteristics.
Protein therapeutics refer to the use of proteins as therapeutic agents to treat various medical conditions and diseases. Unlike traditional small-molecule drugs, protein therapeutics are larger, more complex molecules that often mimic or interfere with natural proteins in the body to modify or regulate biological processes. These therapeutic proteins can be naturally occurring or engineered through biotechnological methods.
Rise in incidence of chronic conditions, including cancer, diabetes, and autoimmune disorders, is propelling demand for innovative therapeutic approaches with proteins, particularly monoclonal antibodies that are playing a pivotal role in addressing these complex medical challenges.
Cancer, a leading cause of morbidity and mortality globally, has witnessed a steady rise in new cases each year. Similarly, the escalating rates of diabetes, both type 1 and type 2, contribute to a substantial burden on healthcare systems.
Proteins, especially monoclonal antibodies, have emerged as crucial agents in the treatment of these chronic conditions. Monoclonal antibodies, designed to mimic the immune system's ability to fight off harmful pathogens, are engineered to target specific proteins involved in disease processes. In cancer treatment, monoclonal antibodies can selectively bind to cancer cells, modulating the immune response and inhibiting tumor growth.
Ongoing research and development efforts continue to refine protein therapeutics, expanding their applications and improving treatment outcomes. Development of next-generation monoclonal antibodies, bispecific antibodies, and other protein-based modalities showcases the commitment to innovation. Thus, surge in incidence of chronic diseases is fueling the global protein therapeutics market growth.
Expiration of patents for key biologics is fueling the biosimilars market. This has provided manufacturers opportunities to develop more affordable alternatives, fostering competition and increasing accessibility to critical biologic therapies. Expiration of patents for established biologics marks the entry of biosimilars into the market.
Biosimilars are biological products that are highly similar to, and have no clinically meaningful differences from, an existing approved reference biologic. The expiration of patents allows other manufacturers to develop and market biosimilars, introducing competition to the market for specific biologic therapies.
Potential for cost savings is a primary catalyst for the rise of biosimilars. Biologics, which are complex and often high-cost therapeutic proteins, contribute significantly to healthcare expenditure. As patents expire and biosimilars enter the market, they are generally priced lower than the originator biologics. This competitive pricing creates opportunities for healthcare systems, providers, and patients to access these vital treatments at reduced costs.
Manufacturers of biosimilars benefit from a streamlined regulatory pathway, designed to ensure the safety, efficacy, and quality of these products. The regulatory framework for biosimilars aims to strike a balance between incentivizing innovation and promoting competition, encouraging manufacturers to invest in the development of biosimilars.
Introduction of biosimilars also plays a role in increasing market competition and improving overall healthcare system sustainability. With multiple manufacturers producing biosimilars for a given biologic, market forces drive prices down, providing cost-effective alternatives for patients and healthcare providers.
In terms of product, the monoclonal antibodies segment accounted for the largest global protein therapeutics market share in 2022. This is ascribed to the pivotal role played by monoclonal antibodies in treating various diseases.
Engineered to mimic the immune system's ability to target specific cells, mAbs are extensively utilized for their precision in binding to disease-related antigens. Ongoing research, technological advancements, and approval of novel therapies are bolstering the monoclonal antibodies segment. With their high specificity and therapeutic potential, monoclonal antibodies are a cornerstone in the rapidly expanding landscape of protein therapeutics.
Based on application, the cancer segment dominated the global protein therapeutics market in 2022. The trend is expected to continue during the forecast period.
Monoclonal antibodies, particularly immune checkpoint inhibitors and antibody-drug conjugates, have revolutionized cancer treatment by specifically targeting cancer cells while minimizing damage to healthy tissues. These protein therapeutics have demonstrated remarkable success in various cancer types, significantly improving patient outcomes and survival rates.
According to protein therapeutics market analysis, North America is expected to witness robust growth in the next few years. This is ascribed to technological advancements, increase in prevalence of chronic diseases, and well-established biopharmaceutical sector.
The region boasts a strong biopharmaceutical industry, particularly in the U.S. Presence of major pharmaceutical companies, research institutions, and skilled workforce fosters innovation and accelerates the development of protein therapeutics. The U.S. FDA's proactive regulatory approach toward biologics and protein-based drugs further supports the rapid entry of novel therapies into the protein therapeutics market.
As per protein therapeutics market research, Asia Pacific witnessed robust growth in 2022. Increase in healthcare infrastructure, large & diverse patient population, rise in prevalence of chronic diseases, and growing emphasis on biopharmaceutical research and development are propelling the market in the region.
The region's healthcare landscape is evolving rapidly, with countries such as China, India, Japan, and South Korea investing significantly in healthcare infrastructure. This growth enhances the accessibility of protein therapeutics, contributing to increased patient demand.
The global protein therapeutics market is fragmented, with the presence of large number of players. Companies are focusing on investment in R&D and collaborations to increase market share.
Thermo Fisher Scientific, Inc., Genzyme Corporation (Sanofi), AbbVie, Inc., Sanofi, Leadiant Biosciences, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo Company, Abbott, and Sanofi are the prominent players in the protein therapeutics market.
Key players have been profiled in the protein therapeutics market report based on parameters such as company overview, latest developments, business strategies, application portfolio, business segments, and financial overview.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 318.4 Bn |
| Forecast (Value) in 2031 | More than US$ 549.4 Bn |
| Growth Rate (CAGR) | 6.3% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 318.4 Bn in 2022.
It is projected to reach more than US$ 549.4 Bn by 2031.
The CAGR is anticipated be 6.3% from 2023 to 2031.
Increase in incidence of chronic diseases, advancements in biotechnology, and growth of biosimilars market
The monoclonal antibodies product segment accounted for more than 49% share in 2022.
North America is expected to account for the largest share from 2023 to 2031.
Thermo Fisher Scientific, Inc., Genzyme Corporation (Sanofi), AbbVie, Inc., Sanofi, Leadiant Biosciences, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo Company, Abbott, and Sanofi.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Protein Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Protein Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Therapeutic monoclonal antibodies approved or in review in the EU or US.
5.2. Regulatory Scenario
5.3. Key Products or Brand Analysis
5.4. Technological Advances in Protein Therapeutics.
5.5. Engineering protein-based therapeutics through structural and chemical design
6. Global Protein Therapeutics Market Analysis and Forecast, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Enzyme Replacement Therapy
6.3.3. Cytokines
6.3.3.1. Interferons
6.3.3.2. Interleukins
6.3.3.3. Growth Factors
6.3.4. Fusion Proteins
6.3.5. Anti-coagulants
6.3.6. Bone Morphogenetic Proteins (BMPs)
6.3.7. Hormones
6.3.8. Others (engineered protein scaffolds, etc.)
6.4. Market Attractiveness Analysis, By Product
7. Global Protein Therapeutics Market Analysis and Forecast, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Metabolic Disorders
7.3.2. Immunologic Disorders
7.3.3. Hematological Disorders
7.3.4. Cancer
7.3.5. Genetic Disorders
7.4. Market Attractiveness Analysis, By Application
8. Global Protein Therapeutics Market Analysis and Forecast, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Injectable Proteins
8.3.2. Oral Proteins
8.4. Market Attractiveness Analysis, By Route of Administration
9. Global Protein Therapeutics Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, By Region
10. North America Protein Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Enzyme Replacement Therapy
10.2.3. Cytokines
10.2.3.1. Interferons
10.2.3.2. Interleukins
10.2.3.3. Growth Factors
10.2.4. Fusion Proteins
10.2.5. Anti-coagulants
10.2.6. Bone Morphogenetic Proteins (BMPs)
10.2.7. Hormones
10.2.8. Others (engineered protein scaffolds, etc.)
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Metabolic Disorders
10.3.2. Immunologic Disorders
10.3.3. Hematological Disorders
10.3.4. Cancer
10.3.5. Genetic Disorders
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Injectable Proteins
10.4.2. Oral Proteins
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Route of Administration
10.6.4. By Country
11. Europe Protein Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Enzyme Replacement Therapy
11.2.3. Cytokines
11.2.3.1. Interferons
11.2.3.2. Interleukins
11.2.3.3. Growth Factors
11.2.4. Fusion Proteins
11.2.5. Anti-coagulants
11.2.6. Bone Morphogenetic Proteins (BMPs)
11.2.7. Hormones
11.2.8. Others (engineered protein scaffolds, etc.)
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Metabolic Disorders
11.3.2. Immunologic Disorders
11.3.3. Hematological Disorders
11.3.4. Cancer
11.3.5. Genetic Disorders
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Injectable Proteins
11.4.2. Oral Proteins
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Route of Administration
11.6.4. By Country/Sub-region
12. Asia Pacific Protein Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Enzyme Replacement Therapy
12.2.3. Cytokines
12.2.3.1. Interferons
12.2.3.2. Interleukins
12.2.3.3. Growth Factors
12.2.4. Fusion Proteins
12.2.5. Anti-coagulants
12.2.6. Bone Morphogenetic Proteins (BMPs)
12.2.7. Hormones
12.2.8. Others (engineered protein scaffolds, etc.)
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Metabolic Disorders
12.3.2. Immunologic Disorders
12.3.3. Hematological Disorders
12.3.4. Cancer
12.3.5. Genetic Disorders
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Injectable Proteins
12.4.2. Oral Proteins
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Route of Administration
12.6.4. By Country/Sub-region
13. Latin America Protein Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Enzyme Replacement Therapy
13.2.3. Cytokines
13.2.3.1. Interferons
13.2.3.2. Interleukins
13.2.3.3. Growth Factors
13.2.4. Fusion Proteins
13.2.5. Anti-coagulants
13.2.6. Bone Morphogenetic Proteins (BMPs)
13.2.7. Hormones
13.2.8. Others (engineered protein scaffolds, etc.)
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Metabolic Disorders
13.3.2. Immunologic Disorders
13.3.3. Hematological Disorders
13.3.4. Cancer
13.3.5. Genetic Disorders
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Injectable Proteins
13.4.2. Oral Proteins
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Route of Administration
13.6.4. By Country/Sub-region
14. Middle East & Africa Protein Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Enzyme Replacement Therapy
14.2.3. Cytokines
14.2.3.1. Interferons
14.2.3.2. Interleukins
14.2.3.3. Growth Factors
14.2.4. Fusion Proteins
14.2.5. Anti-coagulants
14.2.6. Bone Morphogenetic Proteins (BMPs)
14.2.7. Hormones
14.2.8. Others (engineered protein scaffolds, etc.)
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Metabolic Disorders
14.3.2. Immunologic Disorders
14.3.3. Hematological Disorders
14.3.4. Cancer
14.3.5. Genetic Disorders
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Injectable Proteins
14.4.2. Oral Proteins
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By Route of Administration
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Thermo Fisher Scientific, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Material Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Genzyme Corporation (Sanofi)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Material Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. AbbVie, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Material Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Material Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Leadiant Biosciences
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Material Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Takeda Pharmaceutical Company Limited
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Material Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Amicus Therapeutics
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Material Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Bayer AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Material Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Bristol-Myers Squibb
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Material Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. DAIICHI SANKYO COMPANY
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Material Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Abbott
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Material Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Sanofi
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Material Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
List of Tables
Table 01: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 02: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 03: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 04: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 06: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 07: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 08: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 09: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 10: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 11: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 12: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 13: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 14: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 15: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 16: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 18: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 19: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 20: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 21: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 22: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 23: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 24: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
Figure 01: Global Protein Therapeutics Market Size (US$ Mn) Forecast, 2017-2031
Figure 02: Global Protein Therapeutics Market Value Share, by Product (2022)
Figure 03: Global Protein Therapeutics Market Value Share, by Application (2022)
Figure 04: Global Protein Therapeutics Market Value Share, by End-user (2022)
Figure 05: Global Protein Therapeutics Market Value Share, by Region (2022)
Figure 06: Global Protein Therapeutics Market Value Share, by Application, 2022 and 2031
Figure 07: Global Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
Figure 08: Global Protein Therapeutics Market Value Share, by Product, 2022 and 2031
Figure 09: Global Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
Figure 10: Global Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
Figure 11: Global Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
Figure 12: Global Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 13: Global Protein Therapeutics Market Value Share, by Region, 2017-2031
Figure 14: Global Protein Therapeutics Market Attractiveness Analysis, by Region, 2017-2031
Figure 15: North America Protein Therapeutics Market Value Share, by Application, 2022 and 2031
Figure 16: North America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
Figure 17: North America Protein Therapeutics Market Value Share, by Product, 2022 and 2031
Figure 18: North America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
Figure 19: North America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
Figure 20: North America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
Figure 21: North America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 22: North America Protein Therapeutics Market Value Share, by Country, 2017-2031
Figure 23: North America Protein Therapeutics Market Attractiveness Analysis, by Country, 2017-2031
Figure 24: Europe Protein Therapeutics Market Value Share, by Application, 2022 and 2031
Figure 25: Europe Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
Figure 26 : Europe Protein Therapeutics Market Value Share, by Product, 2022 and 2031
Figure 27: Europe Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
Figure 28: Europe Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
Figure 29: Europe Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
Figure 30: Europe Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 31: Europe Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
Figure 32: Europe Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 33: Asia Pacific Protein Therapeutics Market Value Share, by Application, 2022 and 2031
Figure 34: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
Figure 35: Asia Pacific Protein Therapeutics Market Value Share, by Product, 2022 and 2031
Figure 36: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
Figure 37: Asia Pacific Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
Figure 38: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
Figure 39: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 40 : Asia Pacific Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
Figure 41: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 42: Latin America Protein Therapeutics Market Value Share, by Application, 2022 and 2031
Figure 43: Latin America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
Figure 44: Latin America Protein Therapeutics Market Value Share, by Product, 2022 and 2031
Figure 45: Latin America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
Figure 46: Latin America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
Figure 47: Latin America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
Figure 48: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 45: Latin America Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
Figure 50: Latin America Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 51: Middle East & Africa Protein Therapeutics Market Value Share, by Application, 2022 and 2031
Figure 52: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
Figure 53: Middle East & Africa Protein Therapeutics Market Value Share, by Product, 2022 and 2031
Figure 54: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
Figure 55: Middle East & Africa Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
Figure 56: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
Figure 57: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
Figure 58: Middle East & Africa Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
Figure 59: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Protein Therapeutics Market
